Trial Profile
A Multicenter, Randomized, Double-Blind, Phase 3 Study Of Sunitinib Plus Prednisone Versus Prednisone In Patients With Progressive Metastatic Castration-Resistant Prostate Cancer After Failure Of A Docetaxel-Based Chemotherapy Regimen (A6181120)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 14 Oct 2021
Price :
$35
*
At a glance
- Drugs Prednisone (Primary) ; Sunitinib (Primary)
- Indications Prostate cancer
- Focus Registrational; Therapeutic Use
- Sponsors Pfizer
- 14 Oct 2021 This trial has been completed in France (End Date: 21 Dec 2011), according to European Clinical Trials Database record.
- 09 Dec 2013 Results published in the Journal of Clinical Oncology.
- 01 Dec 2011 Primary endpoint 'Overall-survival-duration' has not been met.